Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids
Ron Firestein,1,2,* Cezary Marcinkiewicz,3,4,* Linyan Nie,5 Hui Kheng Chua,1,2 Ines Velazquez Quesada,4 Marco Torelli,6 Mark Sternberg,3 Bojana Gligorijevic,4 Olga Shenderova,6 Romana Schirhagl,5 Giora Z Feuerstein3 1Centre for Cancer Research, Hudson Institute of Medical Research, C...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/069617cff4c94f28a26f7db7ba2c1c87 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:069617cff4c94f28a26f7db7ba2c1c87 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:069617cff4c94f28a26f7db7ba2c1c872021-12-02T19:11:38ZPharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids1177-8903https://doaj.org/article/069617cff4c94f28a26f7db7ba2c1c872021-09-01T00:00:00Zhttps://www.dovepress.com/pharmacodynamic-studies-of-fluorescent-diamond-carriers-of-doxorubicin-peer-reviewed-fulltext-article-NSAhttps://doaj.org/toc/1177-8903Ron Firestein,1,2,* Cezary Marcinkiewicz,3,4,* Linyan Nie,5 Hui Kheng Chua,1,2 Ines Velazquez Quesada,4 Marco Torelli,6 Mark Sternberg,3 Bojana Gligorijevic,4 Olga Shenderova,6 Romana Schirhagl,5 Giora Z Feuerstein3 1Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, 3168, Australia; 2Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, 3800, Australia; 3Debina Diagnostics Inc., Newtown Square, PA, USA; 4College of Engineering, Department of Bioengineering, Temple University, Philadelphia, PA, USA; 5Groningen University, Groningen, 9727, the Netherlands; 6Adámas Nanotechnologies, Inc., Raleigh, NC, 27617, USA*These authors contributed equally to this workCorrespondence: Giora Z FeuersteinDebina Diagnostics Inc., 33 Bishop Hollow Road, Newtown Square, PA, 19073, USATel +4842221575Email giorafeuerstein@gmail.comBackground: We recently reported on preferential deposition of bare fluorescent diamond particles FDP-NV-700/800nm (FDP-NV) in the liver following intravenous administration to rats. The pharmacokinetics of FDP-NV in that species indicated short residency in the circulation by rapid clearance by the liver. Retention of FDP-NV in the liver was not associated with any pathology. These observations suggested that cancer therapeutics, such as doxorubicin, linked to FDP-NV, could potentially serve for anti-cancer treatment while sparing toxicities of peripheral organs.Purpose: To generate proof-of-concept (POC) and detail mechanisms of action of doxorubicin-coated FDP-NV-700/800nm (FDP-DOX) as a prospective chemotherapeutic for metastatic liver cancer.Methods: FDP-DOX was generated by adsorption chemistry. Experimental design included concentration and time-dependent efficacy studies as compared with naïve (baren) FDP-NV in in vitro liver cancer cells models. Uptake of FDP-NV and FDP-DOX by HepG-2, Hep-3B and hCRC organoids were demonstrated by flow-cytometry and fluorescent microscopy. FDP-DOX pharmacodynamic effects included metabolic as well as cell death biomarkers Annexin V, TUNEL and LDH leakage. DOX desorpted from FDP-DOX was assessed by confocal microscopy and chemical assay of cells fractions.Results: FDP-DOX efficacy was dose- and time-dependent and manifested in both liver cancer cell lines and human CRC organoids. FDP-DOX was rapidly internalized into cancer cells/organoids leading to cancer growth inhibition and apoptosis. FDP-DOX disrupted cell membrane integrity as evident by LDH release and suppressing mitochondrial metabolic pathways (AlamarBlue assay). Access of free DOX to the nuclei was confirmed by direct UV-Visible fluorescent assay and confocal microscopy of DOX fluorescence.Conclusion: The rapid uptake and profound cancer inhibition observed using FDP-DOX in clinically relevant cancer models, highlight FDP-DOX promise for cancer chemotherapeutics. We also conclude that the in vitro data justify further investment in in vivo POC studies.Keywords: liver cancer cell-lines, human colorectal cancer organoids, fluorescent diamond particles-NV-700/800nm, doxorubicin, apoptosisFirestein RMarcinkiewicz CNie LChua HKVelazquez Quesada ITorelli MSternberg MGligorijevic BShenderova OSchirhagl RFeuerstein GZDove Medical Pressarticleliver cancer cell-lineshuman colorectal cancer organoidsfluorescent diamond particles-nv-700/800nmdoxorubicinapoptosisMedical technologyR855-855.5Chemical technologyTP1-1185ENNanotechnology, Science and Applications, Vol Volume 14, Pp 139-159 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
liver cancer cell-lines human colorectal cancer organoids fluorescent diamond particles-nv-700/800nm doxorubicin apoptosis Medical technology R855-855.5 Chemical technology TP1-1185 |
| spellingShingle |
liver cancer cell-lines human colorectal cancer organoids fluorescent diamond particles-nv-700/800nm doxorubicin apoptosis Medical technology R855-855.5 Chemical technology TP1-1185 Firestein R Marcinkiewicz C Nie L Chua HK Velazquez Quesada I Torelli M Sternberg M Gligorijevic B Shenderova O Schirhagl R Feuerstein GZ Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| description |
Ron Firestein,1,2,* Cezary Marcinkiewicz,3,4,* Linyan Nie,5 Hui Kheng Chua,1,2 Ines Velazquez Quesada,4 Marco Torelli,6 Mark Sternberg,3 Bojana Gligorijevic,4 Olga Shenderova,6 Romana Schirhagl,5 Giora Z Feuerstein3 1Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, 3168, Australia; 2Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, 3800, Australia; 3Debina Diagnostics Inc., Newtown Square, PA, USA; 4College of Engineering, Department of Bioengineering, Temple University, Philadelphia, PA, USA; 5Groningen University, Groningen, 9727, the Netherlands; 6Adámas Nanotechnologies, Inc., Raleigh, NC, 27617, USA*These authors contributed equally to this workCorrespondence: Giora Z FeuersteinDebina Diagnostics Inc., 33 Bishop Hollow Road, Newtown Square, PA, 19073, USATel +4842221575Email giorafeuerstein@gmail.comBackground: We recently reported on preferential deposition of bare fluorescent diamond particles FDP-NV-700/800nm (FDP-NV) in the liver following intravenous administration to rats. The pharmacokinetics of FDP-NV in that species indicated short residency in the circulation by rapid clearance by the liver. Retention of FDP-NV in the liver was not associated with any pathology. These observations suggested that cancer therapeutics, such as doxorubicin, linked to FDP-NV, could potentially serve for anti-cancer treatment while sparing toxicities of peripheral organs.Purpose: To generate proof-of-concept (POC) and detail mechanisms of action of doxorubicin-coated FDP-NV-700/800nm (FDP-DOX) as a prospective chemotherapeutic for metastatic liver cancer.Methods: FDP-DOX was generated by adsorption chemistry. Experimental design included concentration and time-dependent efficacy studies as compared with naïve (baren) FDP-NV in in vitro liver cancer cells models. Uptake of FDP-NV and FDP-DOX by HepG-2, Hep-3B and hCRC organoids were demonstrated by flow-cytometry and fluorescent microscopy. FDP-DOX pharmacodynamic effects included metabolic as well as cell death biomarkers Annexin V, TUNEL and LDH leakage. DOX desorpted from FDP-DOX was assessed by confocal microscopy and chemical assay of cells fractions.Results: FDP-DOX efficacy was dose- and time-dependent and manifested in both liver cancer cell lines and human CRC organoids. FDP-DOX was rapidly internalized into cancer cells/organoids leading to cancer growth inhibition and apoptosis. FDP-DOX disrupted cell membrane integrity as evident by LDH release and suppressing mitochondrial metabolic pathways (AlamarBlue assay). Access of free DOX to the nuclei was confirmed by direct UV-Visible fluorescent assay and confocal microscopy of DOX fluorescence.Conclusion: The rapid uptake and profound cancer inhibition observed using FDP-DOX in clinically relevant cancer models, highlight FDP-DOX promise for cancer chemotherapeutics. We also conclude that the in vitro data justify further investment in in vivo POC studies.Keywords: liver cancer cell-lines, human colorectal cancer organoids, fluorescent diamond particles-NV-700/800nm, doxorubicin, apoptosis |
| format |
article |
| author |
Firestein R Marcinkiewicz C Nie L Chua HK Velazquez Quesada I Torelli M Sternberg M Gligorijevic B Shenderova O Schirhagl R Feuerstein GZ |
| author_facet |
Firestein R Marcinkiewicz C Nie L Chua HK Velazquez Quesada I Torelli M Sternberg M Gligorijevic B Shenderova O Schirhagl R Feuerstein GZ |
| author_sort |
Firestein R |
| title |
Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| title_short |
Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| title_full |
Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| title_fullStr |
Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| title_full_unstemmed |
Pharmacodynamic Studies of Fluorescent Diamond Carriers of Doxorubicin in Liver Cancer Cells and Colorectal Cancer Organoids |
| title_sort |
pharmacodynamic studies of fluorescent diamond carriers of doxorubicin in liver cancer cells and colorectal cancer organoids |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/069617cff4c94f28a26f7db7ba2c1c87 |
| work_keys_str_mv |
AT firesteinr pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT marcinkiewiczc pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT niel pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT chuahk pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT velazquezquesadai pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT torellim pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT sternbergm pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT gligorijevicb pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT shenderovao pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT schirhaglr pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids AT feuersteingz pharmacodynamicstudiesoffluorescentdiamondcarriersofdoxorubicininlivercancercellsandcolorectalcancerorganoids |
| _version_ |
1718377070694760448 |